# A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis

> **NCT03817424** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 31 (actual)

## Conditions studied

- Systemic Lupus Erythematosus
- Cutaneous Lupus Erythematosus
- Sjogren's Syndrome
- Systemic Sclerosis
- Polymyositis
- Dermatomyositis

## Interventions

- **DRUG:** VIB7734
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03817424
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-13
- **Primary completion:** 2020-07-20
- **Final completion:** 2020-07-20
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2024-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03817424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03817424, "A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03817424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*